Treasury Wine Estates Ltd (ASX: TWE) investors have been strapped into quite the roller coaster. And the ride isn’t over yet.

After a brutal plunge over the past year, Treasury Wine shares have staged a sharp comeback. The ASX wine stock kicked off the new week around 4% higher at $5.36, pushing its six-month gain to roughly 50%.

Impressive stuff, until you zoom out. Over the past 12 months, Treasury Wine shares are still down about 28%.

So which is it: genuine turnaround, or a rebound that’s got ahead of itself?

A radical reset or a radical gamble?

The company’s June strategy reset is doing a lot of heavy lifting here. Treasury Wine is ripping up its old playbook, slashing its brand count from 76 down to fewer than 30 over five years and throwing its weight behind flagship label Penfolds.

The troubled Americas business is under review, and management is chasing roughly $100 million in annualised cost savings by FY29.

The stated goal: fatter margins, a simpler business, and capital funneled toward the brands that can actually move the needle. Treasury Wine is now targeting a long-term EBITS margin above 25%.

The market went wild for it, shares have jumped more than 25% since the day the reset strategy dropped. But strip away the enthusiasm, and there’s a much less comfortable story underneath.

Not so fast, this isn’t a turnaround yet

A share-price rally doesn’t magically erase the problems that caused the crash in the first place. Treasury Wine has already booked a further $558.4 million post-tax non-cash impairment on its US assets — a brutal reminder of just how badly the Americas business has gone off the rails.

FY27 is shaping up as a transition year for Treasury Wine shares, not a victory lap. The entire bull case hinges on management nailing a portfolio overhaul, fixing bloated inventory, actually banking those promised cost savings, and keeping Penfolds growing through it all.

That’s a lot of moving parts, and a lot can still go wrong. The uncomfortable read is that the recent rebound might just be the market getting ahead of itself, pricing in a turnaround before any of those benefits have actually shown up in the numbers.

What do the brokers think?

Analysts are warming up to Treasury Wine shares, but nobody’s fully sold. Morgans has a buy rating and a $7.30 target, recently lifted from $5.95. That suggests a 36% upside from current price levels.

Citi is bullish too, with a buy rating and $6.95 target. UBS sits more cautiously at hold with $6.50, and JPMorgan mirrors that with a $6.00 hold.

Across 16 analysts, the average target lands around $6.25, 17% above Treasury Wine’s current $5.36 price. On paper, that’s real upside if the transformation actually delivers.

Foolish takeaway

After one of the wildest years in Treasury Wine’s history, a 50% six-month rally isn’t proof of anything. It’s a promissory note. Brokers see potential for Treasury Wine shares, but potential and delivery are two very different things.

Until the wine company actually executes on cost cuts, inventory discipline and Penfolds growth, calling this a turnaround might be jumping the gun. Investors watching from the sidelines are right to want to see results before believing the story.

The post Treasury Wine shares: turnaround or trap? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• These are the 10 most shorted ASX shares
• These are the 10 most shorted ASX shares
• What are the most shorted ASX shares on the market right now?
• These are the 10 most shorted ASX shares

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase and Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

You have to go all the way back to June 2019 to find the last time Xero Ltd (ASX: XRO) shares were trading below the $60 mark.

Xero finished Monday at $60.08 after dropping another 4.30%, having touched an intraday low of $59.65.

The last time Xero closed below $60 was 28 June 2019, when the shares finished at $59.94.

That’s pretty remarkable when you consider Xero was trading as high as $196.52 in late June last year.

The selling has been relentless recently as well.

Xero shares are now down almost 30% over the past month and around 47% since the start of 2026.

September has been brutal

What makes the latest slide a little harder to pin down is that Xero hasn’t released any bad news to the market.

There has been no profit warning, earnings downgrade or major operational update behind the recent selling.

Instead, a few things seem to be working against the stock at the same time.

ASX tech shares had another tough session on Monday as expectations for another RBA rate rise increased.

Australian 10-year bond yields were also sitting around 5.3%, which hasn’t helped high-growth tech stocks either.

Xero has also been caught in the software sell-off as investors question what AI could mean for the sector over the next few years.

And then there’s Melio.

The acquisition pushed Xero further into US payments, while bringing extra costs and lower-margin revenue into the business as well.

This isn’t the same Xero as 2019

That’s what makes the current share price hard to ignore.

Xero may be back around its 2019 share price, but the business is now much larger.

In FY26, operating revenue rose 31% to NZ$2.75 billion, while adjusted EBITDA increased 18% to NZ$757.4 million.

Free cash flow reached NZ$554 million, while Xero added another 506,000 customers to finish the year with 4.92 million.

The numbers weren’t all heading in the right direction though.

Net profit fell 27% to NZ$167.4 million, while gross margin dropped from 89% to 83.9% as Melio started contributing to the group.

Xero has also flagged up to NZ$55 million of additional US brand spending during FY27.

Analysts value Xero much higher

The other thing worth watching is just how far Xero has fallen below some analyst valuations.

Morningstar has a fair value estimate of $97.87, although it also gives the stock a high uncertainty rating.

TipRanks shows Citi with a $113.60 price target, while RBC Capital has a more conservative target of $85.

Even the lowest of those figures is still well above yesterday’s close of $60.08.

That doesn’t mean Xero shares can’t keep falling, particularly after the way they’ve traded through September.

But it shows just how quickly the market has changed its view of the stock.

The post Xero shares crash to a 7-year low after a brutal sell-off appeared first on The Motley Fool Australia.

More reading

• Why brokers think Xero shares could surge 130% from here
• 3 ASX 200 shares I’d buy and hold for a decade
• 7 ASX 200 shares with reaffirmed buy ratings this week
• Forget Xero shares! Broker tips this top ASX tech stock for 24% gains
• Xero shares crashed 59%. What do brokers see next?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares got smashed on Monday, plunging 12% to $15.76 after a blockbuster merger announcement. Zoom out, though, and the nuclear healthcare stock is still up 40% year to date — though that gain has shrunk to just 12% over 12 months.

So did the market overreact, or is this the start of something worse?

The deal

Here’s the short version: Telix just agreed to buy Germany’s ITM, one of the biggest players in radioisotope production, for US$1.65 billion.

And Telix isn’t paying with cash. It’s paying with shares – 105.8 million of them, worth about US$1.25 billion. On top of that, it’s taking on US$302 million of ITM’s debt, plus another US$96 million in transaction costs and management payouts.

That’s not all. Telix could end up paying a further US$700 million down the track. That will depend on how ITM’s cancer drug ITM-11 performs — up to US$250 million if it clears FDA approval across three indications, and up to US$450 million if sales blow past US$150 million by 2030.

Once the dust settles, current Telix shareholders will own about 76% of the combined company. ITM’s shareholders will get the other 24%.

Why the market panicked

In plain terms: Telix just diluted itself, big time. Issuing 105.8 million new Telix shares is a serious jump in shares on issue, and that’s really what was crushing the price on Monday. Not doubts about the strategy itself.

The deal still needs shareholder approval at a meeting expected in November, which adds a layer of ‘wait and see’. And the combined company’s 2026 revenue guidance of just over US$1.3 billion isn’t exactly blowing anyone away relative to the price tag. So investors are left weighing genuine strategic upside against real, near-term dilution.

CEO Christian Behrenbruch made the case for why it’s worth it:

ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector.

What do brokers think?

Brokers, for the most part, aren’t panicking. Five of the latest broker ratings are a buy — Canaccord Genuity, Citi, JPMorgan, UBS and Jarden, while RBC Capital is the lone hold.

Where they disagree is on price. Targets range from $19 all the way to $31, suggesting upsides between 21% and 97%. Canaccord just lifted its target to $30.25, Citi sits at $31 and JPMorgan is at $25.58. Jarden nudged up to $21, while UBS trimmed its target to $22 but kept its buy rating intact.

Foolish takeaway

Every one of those price targets sits well above where Telix shares trade today. Brokers clearly like the story, but they just can’t agree on the price tag.

The real test isn’t whether the ITM deal makes strategic sense. It probably does. It’s whether Telix can actually integrate a US$1.65 billion acquisition, hit ITM-11’s regulatory milestones, and prove the dilution was worth it.

Until then, this drop looks more like nerves than a verdict.

The post Telix shares just crashed 12% on merger news. Time to buy the dip? appeared first on The Motley Fool Australia.

More reading

• Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?
• Why are Telix Pharmaceuticals shares on the slide today?
• Telix Pharmaceuticals: ITM merger builds a sector leader
• These are the 10 most shorted ASX shares
• ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.